Imperial College London – Confidence in Concept 2019
Lead Research Organisation:
Imperial College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
- Imperial College London (Lead Research Organisation)
- University College London (Collaboration)
- University of Calgary (Collaboration)
- University of Dundee (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- Cancer Research UK Cambridge Institute (Collaboration)
- Imperial College Healthcare NHS Trust (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Antigen Discovery Inc (Collaboration)
- Volition SPRL (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Beatson Institute for Cancer Research (Collaboration)
- Erasmus University Rotterdam (Collaboration)
People |
ORCID iD |
Publications
Berecz T
(2021)
Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy
in ESC Heart Failure
Coupland CE
(2021)
Structure, mechanism, and inhibition of Hedgehog acyltransferase.
in Molecular cell
Gara E
(2022)
3D culturing of human pluripotent stem cells-derived endothelial cells for vascular regeneration
in Theranostics
Hurault G
(2022)
EczemaPred: A computational framework for personalised prediction of eczema severity dynamics
in Clinical and Translational Allergy
Hurault G
(2022)
Detecting Eczema Areas in Digital Images: An Impossible Task?
in JID innovations : skin science from molecules to population health
Jackson HR
(2023)
Diagnosis of Multisystem Inflammatory Syndrome in Children by a Whole-Blood Transcriptional Signature.
in Journal of the Pediatric Infectious Diseases Society
Ledger EVK
(2023)
XerC Is Required for the Repair of Antibiotic- and Immune-Mediated DNA Damage in Staphylococcus aureus.
in Antimicrobial agents and chemotherapy
Majid QA
(2022)
Application of Human Induced Pluripotent Stem Cell Technology for Cardiovascular Regenerative Pharmacology.
in Methods in molecular biology (Clifton, N.J.)
| Description | ICiC 8 - Foldes - used in Imperial College BSc and MSc in Genes, Drugs and Stem programmes |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | ICiC 8 - Kalofonou |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Access to affordable technologies, such as this, will transform current practices of screening and monitoring of colorectal cancer. Significant benefits are expected in survival rates through a more targeted monitoring diagnostic test, improvements in clinical management through more efficient surgical interventions and access to treatment schemes, as well as economic impact to the healthcare system. |
| Description | Artificial intelligence to guide mechanism-specific electrophenotype-directed treatments forcomplex arrhythmias |
| Amount | £1,197,675 (GBP) |
| Funding ID | RG/F/22/110078 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 08/2027 |
| Description | ICiC 8 - Edwards - Imperial URKI IAA |
| Amount | £78,000 (GBP) |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2022 |
| End | 09/2023 |
| Description | ICiC 8 - Edwards - Rosetrees Trust |
| Amount | £112,500 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2021 |
| End | 12/2022 |
| Description | ICiC 8 - Kalofonou - Educational Grant |
| Amount | £5,500 (GBP) |
| Organisation | AG Leventis Foundation |
| Sector | Charity/Non Profit |
| Country | Cyprus |
| Start | 09/2022 |
| End | 09/2023 |
| Description | ICiC 8 - Ng - Identification of specific electrophenotypes in human persistent AF |
| Amount | £255,728 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 10/2024 |
| Description | ICiC 8 - Tanaka - RAPID and Efficient Eczema Trials (RAPID programme) |
| Amount | £2,492,737 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 08/2027 |
| Description | ICiC 8 - Tanaka - i4i |
| Amount | £753,248 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2023 |
| End | 03/2025 |
| Description | ICiC 8 - Tate CRUK Convergence Science Centre Development Fund |
| Amount | £50,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 04/2022 |
| Description | ICiC 9 - Green MedTech SuperConnector |
| Amount | £57,836 (GBP) |
| Organisation | MedTech SuperConnector |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 05/2023 |
| Description | ICiC9 - Bull - MResMDDE student project budget |
| Amount | £3,000 (GBP) |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2022 |
| Description | ICiC9 - Tregoning - Bactivac |
| Amount | £40,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 07/2023 |
| Description | The role of 3'-Deoxy-3',4'-didehydro-cytidine in the host response to viral infections. |
| Amount | £264,302 (GBP) |
| Funding ID | MR/W023865/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2022 |
| End | 11/2025 |
| Description | Wellcome Trust Discovery Award |
| Amount | £1,800,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2023 |
| End | 10/2030 |
| Description | Yap -ICiC9 - Hydrophobic nanofibrious haemostatic material for trauma |
| Amount | £109,608 (GBP) |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2023 |
| End | 01/2024 |
| Description | idiopathic pulmonary fibrosis project grant |
| Amount | £139,000 (GBP) |
| Organisation | British Lung Foundation (BLF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2024 |
| Title | ICIC 8 - Barr - High throughout assay for quiescence |
| Description | Image-based high-throughout assay for analysis of quiescence in adherent cell lines |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | N/A |
| Title | ICIC 8 - Barr - mRuby-PCNA tagged MCF7 and HMEC cell lines |
| Description | Fluorescently labelled cell lines for monitoring cell cycle perturbations in real time |
| Type Of Material | Cell line |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | N/A |
| Title | ICIC 8 - Byrne - Precision cut lung slice model |
| Description | precision cut lung slice fibrosis model in murine samples |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | This method will be published at the appropriate time and we would be happy to collaborate with interested parties. This is a good method for preclinical assessment of compounds or to understand fibrosis mechanisms. |
| Title | ICIC 8 - Kalofonou - A method for detection of colorectal cancer variants |
| Description | A novel method for variant detection of colorectal cancer specific markers has been designed and tested on variants of the PIK3CA, TP53, KRAS, BRAF and NRAS genes, using a SNP-based LAMP assay designed to distinguish mutant from wild type alleles, tested on synthetic DNA samples. The primer design is complex but has been automated by the use of an automated LAMP primer design script that can predict a range of primers with presented accuracy percentages, allowing the user to narrow down the lab-based optimisation, accelerating therefore the time from single assay design to experimental validation. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | The method is tested for a range of targets and its impact will be defined in the coming months |
| Title | ICIC 8 - Siggins & Sriskandan - VaxHA |
| Description | suite of Lactococcal vectors expressing hyaluronan plus additional vaccine antigens or virulence proteins |
| Type Of Material | Biological samples |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | These could be used as positive control targets for future assays of vaccine induced immunity. Also, ability to study virulence mechanism more precisely than possible in native expressing bacterial species |
| Title | ICiC 8 - Barr - Reporter cell lines |
| Description | Panel of MCF7 reporter cell lines for studying protein mechanism of action |
| Type Of Material | Cell line |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Being used in multiple projects in our lab and a collaborator's lab |
| Title | ICiC 8 - Foldes - Undifferentiated human pluripotent stem cells (hPSCs) possess tumorigenic potential |
| Description | Undifferentiated human pluripotent stem cells (hPSCs) possess tumorigenic potential, and thus, residual undifferentiated hPSCs are one of the major hazards for the risk of tumor formation from hPSC-derived cell therapy products (CTPs). A highly efficient culture (HEC) assay is one of the most sensitive assays for the detection of residual undifferentiated hPSCs among currently available assays. Health and Environmental Sciences Institute, Cell Therapy-TRAcking, Circulation, & Safety committee launched the international multisite study to evaluate the sensitivity and inter-laboratory variability of the HEC assay. The study confirmed that all participating facilities were able to detect 5 and 15 human induced pluripotent stem cells (hiPSCs) spiked into one million hiPSC-derived cardiomyocytes at sufficient rates of colony formation and that the sensitivity of detection was 0.0005%. The evaluation of precision of the assay revealed that repeatability accounts for a main cause of reproducibility depending on the actual number of spiked hiPSCs. The results indicate that the HEC assay is highly sensitive and robust, and that this in vitro methodology can be generally applicable for the evaluation of potential tumorigenicity risk of hPSC-derived CTPs. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | see abstract/brief desciption |
| Title | ICiC 8 - Kalofonou - Colorectal cancer assays have been standardised using a LightCycler and a Lab-on-Chip device |
| Description | Five assays for BRAF p.V600E, KRAS p.G12D, TP53 (p.R175H, p.R248Q, p.R248W) have been optimised for detection of mutant and wild-type alleles using a PCR machine (LightCycler96) and a Lab-on-Chip device. The assays have been prepared for clinical samples, subject to their availability. Applications have been made to biobanks (UK biobank, Royal Marsden biobank, Cambridge university biobank) for the validation of the generated assays using clinically extracted samples. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | Industrial interest expressed by AstraZeneca's research team for Diagnostic Innovation in Near Patient Medical Devices (Oncology & Biopharm), nominated by the Faculty of Medicine's Industry Partnerships and Commercialisation team, Imperial Enterprise to contribute in the development of a lab-free model for clinical use and expand the proposed research plan through funding routes. |
| Title | ICiC 9 - Bentley - Image segmentation |
| Description | Deep learning imaging method |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Currently in use by researchers of HERMES database |
| Title | ICiC 9 - Tate - Screening of peptide libraries against patient samples |
| Description | We adapted a previously reported technique known as Positional scanning-substrate combinatorial libraries (PS-SCL) where recombinant proteases are screened against combinatorial mixtures of short fluorogenic peptides. This allows the identification of potent and selective inhibitors and chemical tools even for individual members of similar protease families such as lysosomal cathepsins or kallikreins. The new method enables target discovery and drug development directly from human patient samples. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | Facilitate identification of overreactive cancer specific proteases |
| Title | ICiC 8 - Barr - Dataset |
| Description | Imaging dataset of MCF7 and HMEC-hTERT cells treated with 1282 secreted proteins and labelled with EdU, Phospho-S807/811-Rb, p21 and p27 |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | N/A |
| Title | ICiC 8 - Tanaka - EczemaNet TLA4AE |
| Description | Eczema images from children with annotated severity scores |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | The collected data will be used to improve EczemaNet, an AI model for automatic detection of eczema severity |
| URL | http://eczemanet.org |
| Title | ICiC 8 - Tate - Cry-EM |
| Description | Cryo-EM structure of HHAT |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | N/A |
| URL | http://doi.org/10.2210/pdb7Q6Z/pdb |
| Title | ICiC 9 - Bentley - Imaging database of CT in stroke |
| Description | 6000+ CT images with clinical data |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | ICiC 9 - Bull - Novel structure of an unloading Knee Brace using a linear actuator |
| Description | A novel mechanical structure was designed and developed to address skin irritation and slippage. Also, we integrated into our first prototype aninertial unit (IMU) to detect when the user needs assistance which is linked to an actuator to activate the unloading system. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | First protoype with automatic unloading |
| Title | ICiC 9 - Green - EMG & Stimulation Database |
| Description | Dataset of EMG recordings and stimulation, not yet established until charge injection limit confirmed and study on group can be performed in coming weeks. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | Able to see EMG activity in healthy volunteers and stimulation artefacts that arise. |
| Description | ICiC 8 - Brown - Pharmacodynamic ELISA |
| Organisation | Volition SPRL |
| Country | Belgium |
| Sector | Private |
| PI Contribution | Initiated plans for development of pharmacodynamic biomarker. Supplied biological samples for testing |
| Collaborator Contribution | Know-how and offer to conduct initial feasibility study at no cost |
| Impact | N/A |
| Start Year | 2022 |
| Description | ICiC 8 - Brown - Stratification biomarker |
| Organisation | Beatson Institute for Cancer Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Know how and compound |
| Collaborator Contribution | Compound evaluation in murine lung cancer models |
| Impact | N/A |
| Start Year | 2022 |
| Description | ICiC 8 - Edwards - Collaboration with Dundee Drug Discovery Unit |
| Organisation | University of Dundee |
| Department | Drug Discovery Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Drug screen using compounds supplied by DDU |
| Collaborator Contribution | DDU provided >250 compounds |
| Impact | None |
| Start Year | 2021 |
| Description | ICiC 8 - Hickmott - United Kingdom Respiratory Gene Therapy Consortium; Oxford |
| Organisation | University of Edinburgh |
| Department | Royal School of Veterinary Studies |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been improving gene expression from lentiviruses and running the alpha-1 antitrypsin deficiency gene therapy program |
| Collaborator Contribution | The Oxford group manufacture lentiviruses and the Edinburgh group uses large animal models as part of a translational pipeline to the clinic |
| Impact | None yet that I directly participated or that my ICiC money was used for |
| Description | ICiC 8 - Hickmott - United Kingdom Respiratory Gene Therapy Consortium; Oxford |
| Organisation | University of Oxford |
| Department | Radcliffe Department of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been improving gene expression from lentiviruses and running the alpha-1 antitrypsin deficiency gene therapy program |
| Collaborator Contribution | The Oxford group manufacture lentiviruses and the Edinburgh group uses large animal models as part of a translational pipeline to the clinic |
| Impact | None yet that I directly participated or that my ICiC money was used for |
| Description | ICiC 8 - Kalofonou - Formation of link between our group and a Gastroenterology Consultant |
| Organisation | Cancer Research UK Cambridge Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | No contributions have been made yet, but discussions on the expression of support in future work has been provided |
| Collaborator Contribution | Discussions in place on clinical translation plans |
| Impact | No outputs yet |
| Start Year | 2021 |
| Description | ICiC 8 - Tate - Developing the first in vivo chemical biology tool for hedgehog acyltransferase |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | In this collaboration, the Tate group mainly worked on the medicinal chemistry of hit-to-lead optimization, including compounds design, synthesis and evaluation on enzyme and cell assays. |
| Collaborator Contribution | The Raynaud team contributed to the PK studies on selected compounds. |
| Impact | A in vivo active tool molecule for hedgehog acyltransferase |
| Start Year | 2021 |
| Description | ICiC 8 - Tate - Study on the effect of hedgehog acyltransferase inhibitor on T cells |
| Organisation | University of Cambridge |
| Department | Cambridge Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The Tate group provided several series of HHAT inhibitors. |
| Collaborator Contribution | The De La Roche lab evaluated these HHAT inhibitors on T cells. |
| Impact | The toxicity and other effects of HHAT inhibitor on T cells were investigated. |
| Start Year | 2022 |
| Description | ICiC 9 - Bentley - Methods Sharing with international database |
| Organisation | Erasmus University Rotterdam |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | We contributed algorithms |
| Collaborator Contribution | They provided data for the algorithms |
| Impact | Two publications under review |
| Start Year | 2022 |
| Description | ICiC 9 - Bentley - Methods Sharing with international database |
| Organisation | University of Calgary |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | We contributed algorithms |
| Collaborator Contribution | They provided data for the algorithms |
| Impact | Two publications under review |
| Start Year | 2022 |
| Description | ICiC 9 - Bidmos - Jeremy Brown (JB) laboratory at UCL |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We generated the antibodies and characterised their binding to pneumococcal cells |
| Collaborator Contribution | Yes - Please enter the currency of the contribution and the amount of any direct financial contribution made underYes - Please enter the currency of the contribution and the amount of any direct financial contribution made underthis collaboration or partnership to the nearest unit.this collaboration or partnership to the nearest unit.NoNoYes - Please enter the currency of the in-kind contribution and give an estimate of the value of the in-kindYes - Please enter the currency of the in-kind contribution and give an estimate of the value of the in-kindcontributions made by your partners to this collaboration or partnership.contributions made by your partners to this collaboration or partnership.£2000NoNoQ6.Q6. Please complete these questions relating to your collaboration or partnership Please complete these questions relating to your collaboration or partnershipPlease enter a short title for thisPlease enter a short title for thiscollaboration or partnership for yourcollaboration or partnership for yourreference purposes.reference purposes.Jeremy Brown (JB) laboratory at UCLPlease provide details of the collaboratorPlease provide details of the collaboratorand/or partner.and/or partner.Target binding partner of our antibodies are being confirmed by mutants that are being generatedat JB lab.Please enter the organisation with whichPlease enter the organisation with whichyou have collaborated or partnered.you have collaborated or partnered.University College London (UCL)Please enter the department with whichPlease enter the department with whichyou collaborated/partnered or enter N/A ifyou collaborated/partnered or enter N/A ifnot applicable. Please do NOT enternot applicable. Please do NOT enterindividual names of people.individual names of people.Respiratory MedicineQ7.Q7. Has this collaboration or partnership brought a direct financial contribution to your research?Q8.Q8. Has this collaboration or partnership brought an in-kind contribution to your research?Q9.Q9.Briefly describe the contributions madeBriefly describe the contributions madeby you and/or your research team to thisby you and/or your research team to thiscollaboration or partnership.collaboration or partnership.We generated the antibodies and characterised their binding to pneumococcal cellsBriefly describe the contributions madeBriefly describe the contributions madeby your partners to this collaboration orby your partners to this collaboration orpartnership.partnership.JB lab kindly provided some pneumococci used in our initial experiments and assessed ability ofantibodies to kill pneumococci in different experiments. JB lab now generating pneumococcalmutants that we will use to confirm identity of the antibodies' target. |
| Impact | No outputs yet. A manuscript detailing work done in this collaboration is currently being drafted. |
| Start Year | 2019 |
| Description | ICiC 9 - Bidmos - Protein array work at ADI |
| Organisation | Antigen Discovery Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | We generated the antibodies and characterised their binding to pneumococci |
| Collaborator Contribution | Determination of the identity of our antibodies' target using their protein array technology |
| Impact | None yet, manuscript drafting in progress |
| Start Year | 2019 |
| Description | ICiC 9 - Mann - QIT benchmarking with AZ |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | generation of samples for analysis |
| Collaborator Contribution | mass spectrometry analysis of samples |
| Impact | none to date |
| Start Year | 2022 |
| Description | ICiC 9 - Sriskandan - ddhC in critically ill children |
| Organisation | Imperial College Healthcare NHS Trust |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | BRC funding obtained by Dr Ramnarayan to investigate ddhC in critically ill children |
| Collaborator Contribution | collecting samples from children on PICU |
| Impact | none at present |
| Start Year | 2022 |
| Title | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER |
| Description | The invention relates to compounds of formula (I) and related compounds and their use in the treatment of cancer, especially platinum resistant cancer. The invention also provides a treatment comprising administration of a compound of formula (I) and a platinum containing drug. |
| IP Reference | WO2021123798 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | Currently in negotiations with a company via Imperial Enterprise to perform an evaluation study, |
| Title | INJECTION DEVICE FOR INJECTION OF BIOLOGICAL MATERIALS |
| Description | An injection device comprising: a first barrel for containing a first fluid, and having a first plunger; a second barrel for containing a second fluid, and having a second plunger, the second barrel being arranged to one side of the first barrel; a flow converging chamber in fluid communication with the second barrel, for receiving, in use, a flow of the second fluid from the second barrel when the second plunger is advanced within the second barrel; a first inlet to the flow converging chamber, in communication with the first barrel, for receiving, in use, a flow of the first fluid from the first barrel when the first plunger is advanced within the first barrel, simultaneously with the advancement of the second plunger, and arranged to introduce the flow of the first fluid in a concentric manner within the flow of the second fluid, at a meeting point within the flow converging chamber, to produce a concentric flow of the first fluid within the second fluid; and an outlet of the flow converging chamber, for outwardly delivering the concentric flow of the first fluid within the second fluid. The first fluid may contain biological materials such as cells, and may for example comprise a hydrogel. The second fluid may comprise an aqueous fluid such as phosphate-buffered saline. Also provided is a method of delivering a concentric flow of a first fluid within a second fluid, using such an injection device. |
| IP Reference | WO2022263797 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | none |
| Title | METHOD OF GENERATING ENDOTHELIAL CELLS |
| Description | The present invention relates to endothelial cells and methods of generating endothelial cells from pluripotent stem cells. |
| IP Reference | WO2021176233 |
| Protection | Patent granted |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | N/A |
| Title | SYSTEMS AND METHODS FOR TREATING CARDIAC ARRHYTHMIA |
| Description | Apparatus for monitoring activation in a heart comprises a probe (100), a plurality of electrodes (102) supported at respective electrode positions on the probe and each arranged to contact a respective detection position on the heart. Each of the electrodes (102) is arranged to detect electrical potential at the respective detection position during movement of a series of activation wavefronts across the heart and to produce a respective electrode signal. Processing means is arranged to analyse the electrode signals to: identify pairs of the electrode signals between which there is a degree of Granger causality; define a causality vector between the electrode positions of each of the pairs of electrodes; identify a potential driver location; and analyse the direction of a plurality of the causality vectors around the potential driver position to generate an indicator of the presence of a driver at the potential driver location. |
| IP Reference | WO2020183157 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | N/A |
| Title | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| Description | The invention generally relates to products for use in the treatment and/or prevention of Pulmonary Arterial Hypertension (PAH). More specifically, the invention relates to translocator protein (TSPO) binding members which treat or prevent pulmonary endothelial cell dysfunction, and the use of such TSPO binding members for use in the treatment and/or prevention of PAH [Figure 1]. |
| IP Reference | WO2022096901 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | N/A |
| Title | ICiC 9 - Green - Wearable Device |
| Description | We are developing our prototype wearable EMG/Stimulator band/medical device. We are developing this device using novel materials in Rylie Green's lab, we have performed proof-of-concept that the materials can record EMG. Now we are moulding the material into a band so can wear it and see the effects of the material and if it can still gather EMG and stimulate effectively. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | N/A |
| Title | ICiC 9 - Stevens - QwikZyme |
| Description | We are developing portable, rapid, and ultrasensitive point-of-care (PoC) diagnostic test ('QwikZyme') that can be very valuable for the fast diagnosis of diverse health conditions in the field. These tests are expected to be low-cost and easy to use by people with no clinical training even for at-home use. We are working with an industrial device design company to manufacture prototypes to be used for initial clinical performance evaluation and validation. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Impact | N/A |
| Title | ICiC 8 - Kalofonou - Automated allele-specific design tool |
| Description | A novel in-silico allele-specific primer design script was designed for automated design of LAMP primers. The tool offers a great solution for fast experimental testing of gene assays and elimination of false-positive amplifications. |
| Type Of Technology | Software |
| Year Produced | 2021 |
| Impact | The tool can be run on a command line on a PC or tablet, removing the complexities of primer manual design and while automating the process of primer design for allele-specific mutations, it improves significantly the steps of experimental validation in terms of accuracy, speed and reproducibility. |
| Title | ICiC 8 - Tanaka - eczemanet.org |
| Description | Web portal for photo upload and eczema severity scoring |
| Type Of Technology | Webtool/Application |
| Year Produced | 2021 |
| Impact | clinical staff can upload eczema images and annotate severity scores easily |
| URL | http://eczemanet.org |
| Title | ICiC 9 - Farina - Wearable Neural Interface for Tremor Suppression |
| Description | a wearable closed-loop neuroprosthetic with the ability to non-invasively monitor the underlying neural activity associated with tremor and apply appropriate electrical stimulation patterns on the surface of the skin. Specifically, we aim to apply low-level electrical stimulation to antagonist muscle pairs simultaneously or out-of-phase to cancel tremor bursts when tremor signals arrive. |
| Type Of Technology | Systems, Materials & Instrumental Engineering |
| Year Produced | 2023 |
| Impact | This device allows for investigations on optimal stimulation parameters for tremor suppression,as well as allowing personal customisation of the stimulator for each patient. Furthermore, it can lead to a compact medical device for tremor suppression in the future. |
| Company Name | Alveogene UK LTD |
| Description | Biotechnology company specializing in respiratory gene therapy |
| Year Established | 2022 |
| Impact | Company was recently formed, no impacts have yet been made |
| Description | ICiC 8 - Brown - OCA Patient and Public Engagement Groups |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Reports on research through Ovarian Cancer Action website leading to increased involvementof patient groups in research applications.. |
| Year(s) Of Engagement Activity | 2022,2023 |
| URL | https://ovarian.org.uk/our-research/ |
| Description | ICiC 8 - Kalofonou - Clinical and Educational Seminars (Melpomeni Kalofonou) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Educational Seminar on "Microchip technology for cancer diagnostics" as part of Imperial'sCentre for Continuing Professional Development (CPD) |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 8 - Kalofonou - Conference Chair (Melpomeni Kalofonou) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chaired the session "Liquid biopsy in Cancer: Emerging relevance in early and advanceddisease" of the 3rd Oncological Congress of Greek Diaspora organised by the Hellenic Society of Oncologists |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 8 - Kalofonou - Conference talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Kalofonou was invited to talk in "Microchip technology for cancer diagnostics" at the 2nd Oncological Congress of Greek Diaspora by the Hellenic Association of Oncologists (October 2021) and a talk in "Lab-on-Chip Diagnostics for Pan-Cancer Screening" at the the 20th Educational Congress "Highlights in Oncology" (December 2021) in Greece |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://livetime.gr/event/2od2021/ |
| Description | ICiC 8 - Kalofonou - Guest Lecture (Melpomeni Kalofonou) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Guest Lecture in Cancer Technologies invited as part of the Biomedical Electronics moduletaught to under graduation and postgraduate students of the Department of Electrical andElectronic Engineering, Imperial College London (Course Lead: Prof. Pantelis Georgiou, co-I) |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 8 - Kalofonou - Imperial College International training workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Kalofonou was invited to give a talk on "Microchip technology for cancer diagnostics" at an Imperial CPD event (Training Program for Oncologists in China, Beijing Huatong Guokang Foundation (BHGF), July 2021) |
| Year(s) Of Engagement Activity | 2021 |
| Description | ICiC 8 - Kalofonou - Talk in Forum |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Mr Simillis presented the latest updates of the project at the Cambridge Surgical Forum |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://surgery.medschl.cam.ac.uk/the-cambridge-surgical-forum/ |
| Description | ICiC 8 - Kalofonou - Talk invited by Imperial Alumni office |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof. Georgiou discussed about the technological developments of his core Lab-on-Chip technology and its applications in the field of diagnostics |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.imperial.ac.uk/events/138552/dr-w-wong-jr/ |
| Description | ICiC 8 - Moore - Kings Maths School |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | I supervised a group of secondary school students who did some mathematical modelling of the injector. |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 9 - Bull - Meetings with a group o patients and experts from the London In Vitro Diagnostics Co-operative |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | We have engaged directly with the musculoskeletal PPI group at Imperial College through the NIHR London IVD. People in this group are experienced lay advisers that have previously expressed an interest in supporting our project. Their role is to help shape the ongoing development of the brace and participate in our next steps of research as well as participate inthe development of the ethics application. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://london.ivd.nihr.ac.uk/patient-public/ |
| Description | ICiC 9 - Bull - Multiple presentations have been delivered to a large group of students, researchers, postdocs and fellows in the Department of Bioengineering |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | MuA group of students, researchers, postdocs and fellows in the Department of Bioengineering have attended to our presentations, showing the project and current developments. |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 9 - Franzoso - DPFS Outline Application |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Application in preparation for submission by the March 2023 deadline |
| Year(s) Of Engagement Activity | 2023 |
| Description | ICiC 9 - Franzoso - Yuhan |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | I gave a presentation and this has lead to an interest in collaborating post-ICiC award |
| Year(s) Of Engagement Activity | 2022 |
| Description | ICiC 9 - Stevens - Great Exhibition Road Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | The Stevens Group hosted a stall showing an activity related to disease diagnostic assays during the Great Exhibition Road Festival. |
| Year(s) Of Engagement Activity | 2022 |